Principal Financial Group Inc. Reduces Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Principal Financial Group Inc. lowered its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 24.3% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 577,727 shares of the biopharmaceutical company’s stock after selling 184,961 shares during the quarter. Principal Financial Group Inc. owned approximately 0.44% of Dynavax Technologies worth $6,436,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of DVAX. Millennium Management LLC purchased a new stake in shares of Dynavax Technologies in the second quarter valued at $17,615,000. Great Point Partners LLC lifted its holdings in Dynavax Technologies by 87.7% in the 2nd quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after purchasing an additional 1,109,080 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Dynavax Technologies during the 3rd quarter worth about $8,291,000. PDT Partners LLC purchased a new stake in shares of Dynavax Technologies during the third quarter worth about $3,967,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Dynavax Technologies during the second quarter worth about $3,144,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th.

Dynavax Technologies Stock Down 0.5 %

Shares of NASDAQ:DVAX opened at $12.77 on Thursday. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $15.01. The stock’s 50-day moving average price is $12.56 and its two-hundred day moving average price is $11.56. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of 98.24 and a beta of 1.33.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.